Send to a Friend Share

Oppenheimer Downgrades Optimer Pharmaceuticals (OPTR) to Perform

November 4, 2009 11:22 AM EST
OPTR Hot Sheet
Rating Summary:
    6 Buy, 3 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 16 | Down: 7 | New: 23
Oppenheimer downgrades Optimer Pharmaceuticals (Nasdaq: OPTR) from Outperform to Perform.

To see more analyst ratings on OPTR Click Here.

Optimer Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing anti-infective products worldwide.

You May Also Be Interested In


Related Categories

Downgrades

Add Your Comment





Follow StreetInsider.com On Twitter